Programmed Death Ligand-1 (PD-L1) Expression in Patients with Non-Small Cell Lung Cancer (NSCLC) with Unusual Metastasis: A Case Series

被引：0
|
作者：
Tsugitomi, R. [1 ]
Nishimura, N. [1 ]
Imai, R. [1 ]
Okafuji, K. [1 ]
Kitamura, A. [1 ]
Tomishima, Y. [1 ]
Jinta, T. [1 ]
Suzuki, K. [2 ]
Tamura, T. [1 ]
机构：
[1] St Lukes Int Hosp, Dept Pulm Med, Thorac Ctr, Tokyo, Japan
[2] St Lukes Int Hosp, Dept Pathol, Tokyo, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3940
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Programmed death ligand-1 expression and occult lymph node metastasis in non-small cell lung cancer
    Mitsui, Suguru
    Tanaka, Yugo
    Jimbo, Naoe
    Doi, Takefumi
    Tane, Shinya
    Hokka, Daisuke
    Maniwa, Yoshimasa
    THORACIC CANCER, 2023, 14 (18) : 1774 - 1781
  • [22] Immunotherapy efficacy of programmed cell death 1 (PD-1) versus programmed death ligand-1 (PD-L1) inhibitors in non-small cell lung cancer (NSCLC) patients: A systematic review and meta-analysis.
    Yang, Danrong
    Cui, Longgang
    Zhang, Yuzi
    Zhao, Zhengyi
    Bai, Yuezong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Effects of Neoadjuvant Therapy on Programmed Cell Death Ligand 1 (PD-L1) Expression and Immune Microenviroment in Non-Small Cell Lung Cancer (NSCLC)
    Tomaszewski, Kristen
    Huynh, Tiffany
    Kem, Marina
    Mino-Kenudson, Mari
    MODERN PATHOLOGY, 2018, 31 : 753 - 754
  • [24] Effects of Neoadjuvant Therapy on Programmed Cell Death Ligand 1 (PD-L1) Expression and Immune Microenviroment in Non-Small Cell Lung Cancer (NSCLC)
    Tomaszewski, Kristen
    Huynh, Tiffany
    Kem, Marina
    Mino-Kenudson, Mari
    LABORATORY INVESTIGATION, 2018, 98 : 753 - 754
  • [25] Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Sequist, Lecia V.
    Shaw, Alice Tsang
    Azzoli, Christopher G.
    Piotrowska, Zofia
    Huynh, Tiffany
    Fulton, Linnea
    Schultz, Katherine
    Hata, Aaron N.
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
    Dempke, Wolfram C. M.
    Fenchel, Klaus
    Dale, Stephen P.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S275 - S279
  • [27] Correlation Between Programmed Death-1 (PD-1) Expression in Tumor Infiltrating Lymphocytes and Programmed Death Ligand-1 (PD-L1) Expression in Non-Small Cell Lung Carcinoma
    Driver, Brandon
    Miller, Ross A.
    Deavers, Michael
    Tacha, David
    Bernicker, Eric
    Cagle, Philip T.
    LABORATORY INVESTIGATION, 2017, 97 : 475A - 475A
  • [28] Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients
    El-Guindy, Dina M.
    Helal, Duaa S.
    Sabry, Nesreen M.
    El-Nasr, Mohamed Abo
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2018, 30 (04) : 125 - 131
  • [29] Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer
    Pan, Yunjian
    Zheng, Difan
    Li, Yuan
    Cai, Xu
    Zheng, Zongli
    Jin, Yan
    Hu, Haichuan
    Cheng, Chao
    Shen, Lei
    Wang, Jian
    Ji, Hongbin
    Sun, Yihua
    Zhou, Xiaoyan
    Chen, Haiquan
    JOURNAL OF THORACIC DISEASE, 2017, 9 (08) : 2579 - 2586
  • [30] Distribution and Expression of Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Carcinomas of the Lung in a Tertiary Care Centre in South India
    Jacob, Sheba S. K.
    TURKISH JOURNAL OF PATHOLOGY, 2021, 37 (02) : 139 - 144
12345